No currently available treatments have been shown to slow the progression of chronic
obstructive pulmonary disease (COPD) or suppress the inflammation in small airways and …

Although chronic obstructive pulmonary disease (COPD) is a major global health problem
with a rising incidence and morbidity, few pharmacotherapeutic advances have been made …

Tobacco smoking is the dominant risk factor for chronic obstructive pulmonary disease
(COPD), but viral and bacterial infections are the major causes of exacerbations in later …

Executive summary Despite substantial progress in reducing the global impact of many non-
communicable diseases, including heart disease and cancer, morbidity and mortality due to …

No currently available drugs prevent the progression of chronic obstructive pulmonary
disease, one of the leading causes of morbidity and mortality worldwide. Several new drugs …

Although long-acting bronchodilators have been an important advance for the management
of chronic obstructive pulmonary disease (COPD), these drugs do not deal with the …

Results of epidemiological studies have shown that chronic obstructive pulmonary disease
(COPD) is frequently associated with comorbidities, the most serious and prevalent being …

Chronic obstructive pulmonary disease (COPD) is a major global health problem which is
increasing throughout the world and a major cause of death. However, current therapies fail …

Chronic obstructive pulmonary disease (COPD) is a readily diagnosable disorder that
responds to treatment. Smoking cessation can reduce symptoms and prevent progression of …

There is a pressing need for more effective drug treatments for COPD. New bronchodilators
include a long-acting anticholinergic tiotropium bromide and a dual β 2-dopamine 2 …